Physician profile
Stephen B Perez
NPI 1003953852
$1,724.15
in general payments reported to CMS, 2019-2025
17 companies · $326 in 2025
The $326 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $106 · 2020: $47.46 · 2021: $177 · 2022: $428 · 2023: $361 · 2024: $279 · 2025: $326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $966.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $965.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $635.38 | 2021-2025 | |
| Exact Sciences Corporation | $183.86 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $150.95 | 2019-2022 | |
| Lilly USA, LLC | $141.20 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $126.83 | 2019-2021 | |
| Horizon Therapeutics Plc | $97.19 | 2022 | |
| Amarin Pharma, INC. | $70.07 | 2019-2020 | |
| Pfizer INC. | $63.17 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $57.14 | 2022-2025 | |
| Esperion Therapeutics, INC. | $43.56 | 2024-2025 | Nexletol |
| Abbvie INC. | $38.09 | 2024 | |
| Novo Nordisk INC | $27.56 | 2025 | Ozempic, Rybelsus |
| Optinose US, INC. | $22.73 | 2025 | |
| Janssen Pharmaceuticals, INC | $18.02 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $17.36 | 2025 | Farxiga |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $16.27 | 2025 | Zoryve |
| Amgen INC. | $14.77 | 2025 | Otezla, Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.